Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacotherapy for nicotine dependence.

Jack E Henningfield1, Reginald V Fant, August R Buchhalter

  • 1Clinical Pharmacology, Pinney Associates, Bethesda, MD, USA.

CA: a Cancer Journal for Clinicians
|September 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitragynine and 7-hydroxy-mitragyine plasma pharmacokinetics in humans after single and 15 multiple oral kratom extract doses.

Journal of analytical toxicology·2026
Same author

Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Safety and Tolerability of Single and Multiple Daily Oral Doses of Dried Kratom Leaf Powder in a Randomized Trial in Healthy Volunteers.

Therapeutic drug monitoring·2026
Same author

Psychedelic research - Going global.

Journal of psychopharmacology (Oxford, England)·2025
Same author

Abuse potential assessment of novel central nervous system active and psychedelic substances for controlled substances act scheduling recommendations.

Journal of psychopharmacology (Oxford, England)·2025
Same journal

Serious mental illness and cancer: A call to action for equitable care.

CA: a cancer journal for clinicians·2026
Same journal

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same journal

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma.

CA: a cancer journal for clinicians·2026
Same journal

Study finds ovarian cancer survivors who are BRCA carriers have a relatively low risk of breast cancer.

CA: a cancer journal for clinicians·2026
Same journal

Radiation therapy, cytogenetic prognostication, novel systemic chemotherapy, and patient perspective in an adult with choroidal melanoma.

CA: a cancer journal for clinicians·2026
Same journal

Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.

CA: a cancer journal for clinicians·2026
See all related articles

Quitting smoking significantly reduces premature death and improves health outcomes at any stage. Effective strategies and pharmacotherapies, including nicotine replacement and bupropion, aid smoking cessation.

Area of Science:

  • Public Health
  • Addiction Medicine
  • Pharmacology

Background:

  • Long-term cigarette smoking causes premature death in approximately 50% of users due to cancer, cardiovascular, and lung diseases.
  • Smoking cessation offers substantial health benefits, with earlier cessation yielding greater advantages.
  • Cessation improves prognosis and quality of life even after smoking-related diseases develop.

Purpose of the Study:

  • To review the impact of smoking cessation on health outcomes.
  • To outline clinical practice guidelines and effective strategies for smoking cessation.
  • To discuss available and emerging pharmacotherapies for tobacco dependence.

Main Methods:

  • Review of US Public Health Service Clinical Practice Guidelines.

Related Experiment Videos

  • Analysis of pharmacotherapies for tobacco dependence, including nicotine replacement and non-nicotine medications.
  • Discussion of combination therapies, long-term medication use, and harm reduction strategies.

    • Main Results:

    • Smoking cessation, particularly when initiated early, substantially reduces mortality risk.
    • Clinician guidance and structured cessation methods are effective in reducing tobacco use.
    • Nicotine replacement therapies (gum, patch, lozenge, etc.) and bupropion are FDA-approved treatments.
    • New medications like varenicline show promise for treatment-refractory individuals.

    Conclusions:

    • Smoking cessation is a critical intervention for reducing premature mortality and improving health.
    • Clinicians play a vital role in promoting cessation through evidence-based strategies and pharmacotherapy.
    • Expanding access to and reducing the cost of smoking cessation treatments can enhance public health impact.